869357-63-1

Basic information

• Product Name: Methyl 5-broMo-2-chloro-1,6-dihydro-1-Methyl-6-oxopyridine-3-carboxylate
• Synonyms: Methyl 5-broMo-2-chloro-1,6-dihydro-1-Methyl-6-oxopyridine-3-carboxylate;Methyl 5-bromo-2-chloro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate
• CAS NO: 869357-63-1
• Molecular Formula: C8H7BrClNO3
• Molecular Weight: 280.50308
• EINECS: -0
• Mol File: 869357-63-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 5-broMo-2-chloro-1,6-dihydro-1-Methyl-6-oxopyridine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-broMo-2-chloro-1,6-dihydro-1-Methyl-6-oxopyridine-3-carboxylate(869357-63-1)
• EPA Substance Registry System: Methyl 5-broMo-2-chloro-1,6-dihydro-1-Methyl-6-oxopyridine-3-carboxylate(869357-63-1)

Safety Data

• Hazardous Substances Data: 869357-63-1(Hazardous Substances Data)

Usage

Description

Methyl 5-bromo-2-chloro-1,6-dihydro-1-methyl-6-oxopyridine-3-carboxylate is a heterocyclic chemical compound with the molecular formula C8H8BrClNO3. It features a pyridine ring with a bromine and a chlorine atom as substituents, making it a versatile intermediate for various applications.
Used in Pharmaceutical Industry:
Methyl 5-bromo-2-chloro-1,6-dihydro-1-methyl-6-oxopyridine-3-carboxylate is used as a building block for the synthesis of pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs with potential therapeutic effects.
Used in Agrochemical Industry:
Methyl 5-broMo-2-chloro-1,6-dihydro-1-Methyl-6-oxopyridine-3-carboxylate is also utilized as a building block in the synthesis of agrochemicals, contributing to the development of products for agricultural applications such as pesticides and herbicides.
Used in Production of Intermediates:
Methyl 5-bromo-2-chloro-1,6-dihydro-1-methyl-6-oxopyridine-3-carboxylate serves as a versatile intermediate for the production of various compounds in the pharmaceutical industry. Its ability to be further modified enables the creation of a wide range of products for different uses.

Upstream product

• 853109-24-7 methyl 2-chloro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 
• 38025-90-0 2-chloro-6-oxo-1,6-dihydropyridine-3-carboxylic acid 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 

Downstream Products

• 869357-67-5 2-(2-fluoro-4-iodo-anilino)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid methyl ester 
• 869357-68-6 2-[(2-fluoro-4-iodoiodophenyl)amino]-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide 
• 934639-06-2 2-(2-fluoro-4-iodophenylamino)-1,5-dimethyl-6-oxo-N-(2-(vinyloxy)ethoxy)-1,6-dihydropyridine-3-carboxamide 

Relevant articles and documents

Aryl spiro SHP2 inhibitor compound as well as preparation method and application thereof

The invention discloses an aryl spiro SHP2 inhibitor compound as well as a preparation method and application thereof. The invention particularly relates to a nitrogen-containing aryl spiro compound shown as a general formula I (See the specification), or pharmaceutically acceptable salt thereof, or an enantiomer, diastereoisomer, tautomer, solvate, polymorphic substance or prodrug thereof, a preparation method thereof and application thereof in pharmacy, and the definition of each group is shown in the specification.

COMBINATION THERAPY COMPRISING AZD2171 AND AZD6244 OR MEK-INHIBITOR II

The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of AZD2171 in combination with AZD6244 or MEK Inhibitor II; to a pharmaceutical composition comprising AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II; to a combination product comprising AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II; to the use of AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.

HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF

Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.